ProShares UltraPro Short NASDAQ Biotechnology
ZBIOZenas BioPharma is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative immunology-based therapies.
Table of contents
Earnings
Next report
Aug 11, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Zenas BioPharma is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative immunology-based therapies. The company leverages a disciplined acquisition strategy and internal expertise to build a pipeline of product candidates targeting autoimmune diseases. Its core value proposition centers on differentiated mechanisms of action, such as B cell inhibition without depletion, to address chronic inflammatory and immunologic conditions.
A clinical-stage developer focused on differentiated B cell therapies that avoid the risks of prolonged B cell depletion associated with current market standards.
Questions, answered.
- What is ProShares UltraPro Short NASDAQ Biotechnology's market cap?
- ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) has a market capitalization of $1.9B and trades on XNAS.
- Who are ProShares UltraPro Short NASDAQ Biotechnology's competitors?
- ProShares UltraPro Short NASDAQ Biotechnology's key competitors include Amgen Inc., Zura Bio Limited Class A Ordinary Shares, Liminatus Pharma, Inc. Class A Common Stock, and others. These companies compete in similar markets and product categories.
- Who does ProShares UltraPro Short NASDAQ Biotechnology partner with?
- ProShares UltraPro Short NASDAQ Biotechnology's notable partners include Bristol Myers Squibb & Co., InnoCare Pharma, Viridian Therapeutics, Inc., and others.
- Where is ProShares UltraPro Short NASDAQ Biotechnology headquartered?
- ProShares UltraPro Short NASDAQ Biotechnology is headquartered in United States of America. It has been publicly traded since 2024.